BioTek reMEDys and its subsidiaries have entered into an agreement with TidalHealth to manage an infusion suite specifically for the new monoclonal antibodies produced by Eli Lilly and Regeneron.
The infusion suite, near TidalHealth’s hospital in Salisbury, MD, opened and began treating patients in mid-December.
The importance of and demand for providing these treatments, under the FDA’s Emergency Use Approval, led to the collaboration between BioTek reMEDys and TidalHealth to open the infusion suite quickly and with the utmost safety. The urgency of COVID-19 created an environment for two healthcare organizations to collaborate and utilize each other’s best practices to swiftly achieve an end goal.
“When health services organizations put the patient first and leave their egos out, it becomes possible to collaborate in ways that surpass anything an individual organization can achieve,” said Chai Gadde, CEO and founder of the BioTek group of companies.
From a business operations perspective, the infusion suite was designed to be fluid in its ability to scale up to meet volume demand and to provide other therapies as needed.
About BioTek reMEDys
Founded in 2011, BioTek reMEDys, based in New Castle, DE, has become one of the nation’s largest independent infusion pharmacies focused on home infusion and infusion suites. Delaware entrepreneur, investor and philanthropist Chai Gadde opened the pharmacy to meet the needs of patients who require specialty medications but desire the feeling of an independent neighborhood pharmacy. Its national footprint now includes locations in Houston and Phoenix. For information visit www.biotekrx.com.
About TidalHealth
TidalHealth -- which includes TidalHealth Peninsula Regional, TidalHealth Nanticoke, TidalHealth McCready Pavilion and an expansive physician network with 250 providers in 22 different specialties -- provides a full range of patient-centered services, including neurosurgery, cardiothoracic surgery, joint replacement, emergency/trauma care, comprehensive cancer care, women’s and children’s services, wound care and clinical trials and research as a member of the Johns Hopkins Clinical Research Network. Learn more at tidalhealth.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005533/en/
Source: BioTek reMEDys
View this news release online at:
http://www.businesswire.com/news/home/20201222005533/en
